A Novel Therapy for cocaine dependence during abstinence
A randomized clinical trial
Keywords:
Topiramate, Contingency Management, Craving, Anticonvulsants/adverse effects, Pharmacotherapy, Cocaine DependenceAbstract
Background: Topiramate is an anticonvulsant drug and an ideal candidate for reducing the craving in people relying on cocaine. Contingency management is one of the common therapies in the domain of addiction.
Objective: The present study aimed to evaluate and compare three medication methods of Topiramate (TPM), Contingency Management (CM) and the combined TPM treatment and cash intervention on craving during abstinence.
Methods: This randomized clinical trial was conducted at Bijan Center for Substance Abuse Treatment in Tehran, Iran, from December 15, 2014 to November 20, 2015. One hundred males (Age range=18–34; SD=4.11) undergoing abstinence were assigned randomly to four groups (n=25) of Topiramate (TPM), Contingency Management (CM) and the Combined Method plus a placebo control group. Treatment was provided for twelve weeks for the experiment groups, and only the control group received the placebo. Participants in the Cash-based and CM Condition had an identical 12-week escalating schedule of reinforcement (cash-based incentives worth $0, $20, $40, and $80). Also, in the Topiramate group, participants’ dosage ranged between 25-300 mg/day in escalating doses) 25, 50, 100, 150, 200, 250, 300). In addition, all subjects received brief behavioral compliance enhancement treatment (BBCET). Participants took a urine test twice a week, with a given threshold of > 300 ng/ml, and indicators of cocaine craving (response rate= 91%) was evaluated in two phases of pre-test and post-test. We used Chi square, ANCOVA Univariate Model and Scheffe’s post hoc to analyze the primary and secondary outcomes. Also, the qualitative data resulted from demographic evaluations were coded and analyzed by the instrument of analysis of qualitative data i.e. Atlas.ti, Version 5.2.
Results: The results showed that all three types of treatment played a significant efficacy in reducing the craving. The mean (95% CI) scores of craving was 12.04 (p=0.05) with TPM, 13.89 (p=0.05) with CM, 10.92 (p=0.01) with Mix and 16.89 (p>0.05) with control. Moreover, the highest variance explaining the changes in craving was assigned to the combined treatment (p<0.01).
Conclusions: The findings of this study, while having applicable aspects in this domain, can be helpful in planning supplementary remedial procedures.
Trial registration: The trial was registered at the Thai Clinical Trial Registration Center with the TCR ID: TCTR20170112001.
Funding: The authors received no financial support for the research, authorship, and/or publication of this article.
References
Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK. Cystine/glutamate exchange regulates
metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to
cocaine seeking. J Neurosci. 2005; 25(27): 6389-93. doi: 10.1523/JNEUROSCI.1007-05.2005. PMID:
, PMCID: PMC1413952.
Peters J, LaLumiere RT, Kalivas PW. Infralimbic prefrontal cortex is responsible for inhibiting cocaine
seeking in extinguished rats. J Neurosci. 2008; 28(23): 6046-53. doi: 10.1523/JNEUROSCI.1045-08.2008.
PMID: 18524910, PMCID: PMC2585361.
Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci. 2009; 10(8): 561-72.
doi: 10.1038/nrn2515. PMID: 19571793.
Siniscalchi A, Bonci A, Biagio Mercuri N, Pirritano D, Squillace A, De Sarro G, et al. The Role of
Topiramate in the Management of Cocaine Addiction: a Possible Therapeutic Option. Curr
Neuropharmacol. 2015; 13(6): 815-8. doi: 10.2174/1570159x13666150729222643. PMID: 26630959,
PMCID: PMC4759320.
Alves OL, Doyle AJ, Clausen T, Gilman C, Bullock R. Evaluation of topiramate neuroprotective effect in
severe TBI using microdialysis. Ann N Y Acad Sci. 2003; 993: 25-34. doi: 10.1111/j.1749- 6632.2003.tb07508.x. PMID: 12853292.
Minozzi S, Amato L, Davoli M, Farrell M, Lima Reisser AA, Pani PP, et al. Anticonvulsants for cocaine
dependence. Cochrane Database Syst Rev. 2008; (2): CD006754. doi: 10.1002/14651858.CD006754.pub2.
PMID: 18425968.
Vocci F, Ling W. Medications development: successes and challenges. Pharmacology & therapeutics.
; 108(1): 94-108. doi: 10.1016/j.pharmthera.2005.06.010. PMID: 16083966.
Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, et al. A pilot trial of topiramate
for the treatment of cocaine dependence. Drug Alcohol Depend. 2004; 75(3): 233-40. doi:
1016/j.drugalcdep.2004.03.008. PMID: 15283944.
Johnson BA. Recent advances in the development of treatments for alcohol and cocaine dependence: focus
on topiramate and other modulators of GABA or glutamate function. CNS Drugs. 2005; 19(10): 873-96.
doi: 10.2165/00023210-200519100-00005. PMID: 16185095.
Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for
treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003; 361(9370): 1677-85. doi:
1016/S0140-6736(03)13370-3. PMID: 12767733.
Baltieri DA, Daró FR, Ribeiro PL, De Andrade AG. Comparing topiramate with naltrexone in the treatment
of alcohol dependence. Addiction. 2008; 103(12): 2035-44. doi: 10.1111/j.1360-0443.2008.02355.x.
PMID: 18855810.
Rubio G, Martínez-Gras I, Manzanares J. Modulation of impulsivity by topiramate: implications for the
treatment of alcohol dependence. J Clin Psychopharmacol. 2009; 29(6): 584-9. doi:
1097/JCP.0b013e3181bfdb79. PMID: 19910725.
Anthenelli RM, Blom TJ, McElroy SL, Keck PE Jr. Preliminary evidence for gender‐specific effects of
topiramate as a potential aid to smoking cessation. Addiction. 2008; 103(4): 687-94. doi: 10.1111/j.1360- 0443.2008.02148.x. PMID: 18339115.
Khoromi S, Patsalides A, Parada S, Salehi V, Meegan JM, Max MB. Topiramate in chronic lumbar
radicular pain. J Pain. 2005; 6(12): 829-36. doi: 10.1016/j.jpain.2005.08.002. PMID: 16326371.
Nickel MK, Nickel C, Kaplan P, Lahmann C, Mühlbacher M, Tritt K, et al. Treatment of aggression with
topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry. 2005;
(5): 495-9. doi: 10.1016/j.eurpsy.2007.09.004. PMID: 15737664.
Nickel C, Lahmann C, Tritt K, Muehlbacher M, Kaplan P, Kettler C, et al. Topiramate in treatment of
depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo- controlled study. J Affect Disord. 2005; 87(2-3): 243-52. doi: 10.1016/j.jad.2005.04.003. PMID: 15985295.
Nickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK, et al. Topiramate treatment of
aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J
Clin Psychiatry. 2004; 65(11): 1515-9. doi: 10.4088/jcp.v65n1112. PMID: 15554765.
Van Ameringen M, Mancini C, Patterson B, Bennett M. Topiramate augmentation in treatment‐resistant
obsessive–compulsive disorder: a retrospective, open‐label case series. Depress Anxiety. 2006; 23(1): 1- 5. doi: 10.1002/da.20118. PMID: 16178009.
Kampman KM, Pettinati HM, Lynch KG, Spratt K, Wierzbicki MR, O’Brien CP. A double-blind, placebo- controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol
Depend. 2013; 133(1): 94-9. doi: 10.1016/j.drugalcdep.2013.05.026. PMID: 23810644, PMCID:
PMC3786029.
Johnson BA, Ait-Daoud N, Wang XQ, Penberthy JK, Javors MA, Seneviratne C, et al. Topiramate for the
treatment of cocaine addiction: a randomized clinical trial. JAMA psychiatry. 2013; 70(12): 1338-46. doi:
1001/jamapsychiatry.2013.2295. PMID: 24132249.
Knapp CM, Mercado M, Markley TL, Crosby S, Ciraulo DA, Kornetsky C. Zonisamide decreases ethanol
intake in rats and mice. Pharmacol Biochem Behav. 2007; 87(1): 65-72. doi: 10.1016/j.pbb.2007.04.001.
PMID: 17482246, PMCID: PMC2867456.
Hargreaves GA, McGregor IS. Topiramate moderately reduces the motivation to consume alcohol and has
a marked antidepressant effect in rats. Alcohol Clin Exp Res. 2007; 31(11): 1900-7. doi: 10.1111/j.1530- 0277.2007.00485.x. PMID: 17877781.
Cagetti E, Baicy KJ, Olsen RW. Topiramate attenuates withdrawal signs after chronic intermittent ethanol
in rats. Neuroreport. 2004; 15(1): 207-10. doi: 10.1097/00001756-200401190-00040. PMID: 15106859. 24) Elkashef A, Kahn R, Yu E, Iturriaga E, Li SH, Anderson A, et al. Topiramate for the treatment of
methamphetamine addiction: a multi‐center placebo‐controlled trial. Addiction. 2012; 107(7): 1297- 306. doi: 10.1111/j.1360-0443.2011.03771.x. PMID: 22221594, PMCID: PMC3331916.
Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R, Badger GJ. Incentives improve outcome in
outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry. 1994; 51(7): 568-76. doi:
1001/archpsyc.1994.03950070060011. PMID: 8031230.
Griffith JD, Rowan-Szal GA, Roark RR, Simpson DD. Contingency management in outpatient methadone
treatment: a meta-analysis. Drug Alcohol Depend. 2000; 58(1-2): 55-66. doi: 10.1016/s0376- 8716(99)00068-x. PMID: 10669055.
Petry NM, Martin B, Cooney JL, Kranzler HR. Give them prizes and they will come: Contingency
management for treatment of alcohol dependence. J Consult Clin Psychol. 2000; 68(2): 250-7. doi:
1037/0022-006x.68.2.250. PMID: 10780125.
Schepis TS, Duhig AM, Liss T, McFetridge A, Wu R, Cavallo DA, et al. Contingency management for
smoking cessation: Enhancing feasibility through use of immunoassay test strips measuring cotinine.
Nicotine Tob Res. 2008; 10(9): 1495-501. doi: 10.1080/14622200802323209. PMID: 19023841, PMCID:
PMC3679884.
Volpp KG, John LK, Troxel AB, Norton L, Fassbender J, Loewenstein G. Financial incentive–based
approaches for weight loss: a randomized trial. Jama. 2008; 300(22): 2631-7. doi: 10.1001/jama.2008.804.
PMID: 19066383, PMCID: PMC3583583.
Volpp KG, Loewenstein G, Troxel AB, Doshi J, Price M, Laskin M, et al. A test of financial incentives to
improve warfarin adherence. BMC Health Serv Res. 2008; 8: 272. doi: 10.1186/1472-6963-8-272. PMID:
, PMCID: PMC2635367.
Volpp KG, Troxel AB, Pauly MV, Glick HA, Puig A, Asch DA, et al. A randomized, controlled trial of
financial incentives for smoking cessation. N Engl J Med. 2009; 360(7): 699-709. doi:
1056/NEJMsa0806819. PMID: 19213683.
Petry NM, Tedford J, Martin B. Reinforcing compliance with non-drug–related activities. J Subst Abuse
Treat. 2001; 20(1): 33-44. doi: 10.1016/s0740-5472(00)00143-4. PMID: 11239726.
Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of
substance use disorders: A meta‐analysis. Addiction. 2006; 101(11): 1546-60. doi: 10.1111/j.1360- 0443.2006.01581.x. PMID: 17034434.
Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins ST. A meta ‐analysis of voucher‐based
reinforcement therapy for substance use disorders. Addiction. 2006; 101(2): 192-203. doi: 10.1111/j.1360- 0443.2006.01311.x. PMID: 16445548.
Stitzer ML, Vandrey R. Contingency management: utility in the treatment of drug abuse disorders. Clin
Pharmacol Ther. 2008; 83(4): 644-7. doi: 10.1038/sj.clpt.6100508. PMID: 18305456.
Peirce JM, Petry NM, Stitzer ML, Blaine J, Kellogg S, Satterfield F, et al. Effects of lower-cost incentives
on stimulant abstinence in methadone maintenance treatment: A National Drug Abuse Treatment Clinical
Trials Network study. Arch Gen Psychiatry. 2006; 63(2): 201-8. doi: 10.1001/archpsyc.63.2.201. PMID:
Carroll KM, Ball SA, Nich C, O'Connor PG, Eagan DA, Frankforter TL, et al. Targeting behavioral
therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and
significant other involvement. Arch Gen Psychiatry. 2001; 58(8): 755-61. doi: 10.1001/archpsyc.58.8.755.
PMID: 11483141, PMCID: PMC3651594.
Carroll KM, Sinha R, Nich C, Babuscio T, Rounsaville BJ. Contingency management to enhance
naltrexone treatment of opioid dependence: a randomized clinical trial of reinforcement magni
Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR. Improvement in naltrexone
treatment compliance with contingency management. Drug Alcohol Depend. 1999; 54(2): 127-35. doi:
1016/s0376-8716(98)00152-5. PMID: 10217552.
Marlatt GA. Integrating contingency management with relapse prevention skills: Comment on Silverman et
al. Exp Clin Psychopharmacol. 2001; 9(1): 33-4. doi: 10.1037/1064-1297.9.1.33. PMID: 11519633.
Silverman K, Svikis D, Wong CJ, Hampton J, Stitzer ML, Bigelow GE. A reinforcement-based therapeutic
workplace for the treatment of drug abuse: three-year abstinence outcomes. Exp Clin Psychopharmacol.
; 10(3): 228-40. doi: 10.1037/1064-1297.10.3.228. PMID: 12233983.
Corby EA, Roll JM, Ledgerwood DM, Schuster CR. Contingency management interventions for treating
the substance abuse of adolescents: a feasibility study. Exp Clin Psychopharmacol. 2000; 8(3): 371-6. doi:
1037/1064-1297.8.3.371. PMID: 10975628.
Stitzer ML, Bigelow GE, Liebson I. Reducing benzodiazepine self-administration with contingent
reinforcement. Addict Behav. 1979; 4(3): 245-52. doi: 10.1016/0306-4603(79)90034-0. PMID: 495248.
Stitzer ML, Rand CS, Bigelow GE, Mead AM. Contingent payment procedures for smoking reduction and
cessation. J Appl Behav Anal. 1986; 19(2): 197-202. doi: 10.1901/jaba.1986.19-197. PMID: 3733589,
PMCID: PMC1308058.
Higgins ST, Stitzer ML, Bigelow GE, Liebson IA. Contingent methadone delivery: Effects on illicit-opiate
use. Drug Alcohol Depend. 1986; 17(4): 311-22. doi: 10.1016/0376-8716(86)90080-3. PMID: 3757767.
Robles E, Stitzer ML, Strain EC, Bigelow GE, Silverman K. Voucher-based reinforcement of opiate
abstinence during methadone detoxification. Drug and alcohol dependence. 2002; 65(2): 179-89. doi:
1016/s0376-8716(01)00160-0. PMID: 11772479.
Budney AJ, Higgins ST, Radonovich KJ, Novy PL. Adding voucher-based incentives to coping skills and
motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin
Psychol. 2000; 68(6): 1051-61. doi: 10.1037/0022-006x.68.6.1051. PMID: 11142539.
Sigmon SC, Steingard S, Badger GJ, Anthony SL, Higgins ST. Contingent reinforcement of marijuana
abstinence among individuals with serious mental illness: A feasibility study. Exp Clin Psychopharmacol.
; 8(4): 509-17. doi: 10.1037/1064-1297.8.4.509. PMID: 11127422.
Rawson RA, Gonzales R, Brethen P. Treatment of methamphetamine use disorders: an update. J Subst
Abuse Treat. 2002; 23(2): 145-50. doi: 10.1016/s0740-5472(02)00256-8. PMID: 12220612.
Roll JM, Petry NM, Stitzer ML, Brecht ML, Peirce JM, McCann MJ, et al. Contingency management for
the treatment of methamphetamine use disorders. Am J Psychiatry. 2006; 163(11): 1993-9. doi:
1176/ajp.2006.163.11.1993. PMID: 17074952.
Shoptaw S, Klausner JD, Reback CJ, Tierney S, Stansell J, Hare CB, et al. A public health response to the
methamphetamine epidemic: the implementation of contingency management to treat methamphetamine
dependence. BMC public health. 2006; 6: 214. doi: 10.1186/1471-2458-6-214. PMID: 16919170, PMCID:
PMC1559698.
Strona FV, McCright J, Hjord H, Ahrens K, Tierney S, Shoptaw S, et al. The acceptability and feasibility of
the Positive Reinforcement Opportunity Project, a community-based contingency management
methamphetamine treatment program for gay and bisexual men in San Francisco. J Psychoactive Drugs.
; Suppl 3: 377-83. doi: 10.1080/02791072.2006.10400601. PMID: 17357529.
First M, Spitzer R, Gibbon M, Williams J. Biometrics Research. New York State Psychiatric Institute; New
York: 2002. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient
Edition. Clinical Trials Version (SCID-CT).
Sharifi V, Assadi SM, Mohammadi MR, Amini H, Kaviani H, Semnani Y, et al. A Persian translation of
the structured clinical interview for diagnostic and statistical manual of mental disorders: psychometric
properties. Compr Psychiatry. 2009; 50(1): 86-91. doi: 10.1016/j.comppsych.2008.04.004. PMID:
Tiffany ST, Singleton E, Haertzen CA, Henningfield JE. The development of a cocaine craving
questionnaire. Drug Alcohol Depend. 1993; 34(1): 19-28. doi: 10.1016/0376-8716(93)90042-o. PMID:
Sussner BD, Smelson DA, Rodrigues S, Kline A, Losonczy M, Ziedonis D. The validity and reliability of a
brief measure of cocaine craving. Drug Alcohol Depend. 2006; 83(3): 233-7. doi:
1016/j.drugalcdep.2005.11.022. PMID: 16384655.
Singh M, Keer D, Klimas J, Wood E, Werb D. Topiramate for cocaine dependence: a systematic review
and meta ‐ analysis of randomized controlled trials. Addiction. 2016; 111(8): 1337-46. doi:
1111/add.13328. PMID: 26826006.
Nguyen SA, Malcolm R, Middaugh LD. Topiramate reduces ethanol consumption by C57BL/6 mice.
Synapse. 2007; 61(3): 150-6. doi: 10.1002/syn.20350. PMID: 17146766.
Breslin FJ, Johnson BA, Lynch WJ. Effect of topiramate treatment on ethanol consumption in rats.
Psychopharmacology (Berl). 2010; 207(4): 529-34. doi: 10.1007/s00213-009-1683-4. PMID: 19823810,
PMCID: PMC4142502.
Zalewska-Kaszubska J, Bajer B, Gorska D, Andrzejczak D, Dyr W, Bieńkowski P. Effect of repeated
treatment with topiramate on voluntary alcohol intake and beta-endorphin plasma level in Warsaw alcohol
high-preferring rats. Psychopharmacology (Berl). 2013; 225(2): 275-81. doi: 10.1007/s00213-012-2812-z.
PMID: 22847457, PMCID: PMC3536943.
Cohen J, Dervaux A, Laqueille X. [Topiramate in substance-related and addictive disorders]. Presse Med.
; 43(9): 892-901. doi: 10.1016/j.lpm.2014.02.030. PMID: 25027463.
Nuijten M, Blanken P, van den Brink W, Hendriks V. Treatment of crack-cocaine dependence with
topiramate: A randomized controlled feasibility trial in The Netherlands. Drug Alcohol Depend. 2014; 138:
-84. doi: 10.1016/j.drugalcdep.2014.02.024. PMID: 24629631.
Reis AD, Castro LA, Faria R, Laranjeira R. Craving decrease with topiramate in outpatient treatment for
cocaine dependence: an open label trial. Rev Bras Psiquiatr. 2008; 30(2): 132-5. doi: 10.1590/s1516- 44462008005000012. PMID: 18470406.
Kirby KC, Carpenedo CM, Dugosh KL, Rosenwasser BJ, Benishek LA, Janik A, et al. Randomized clinical
trial examining duration of voucher-based reinforcement therapy for cocaine abstinence. Drug Alcohol
Depend. 2013; 132(3): 639-45. doi: 10.1016/j.drugalcdep.2013.04.015. PMID: 23680075, PMCID:
PMC3770760.
Festinger DS, Dugosh KL, Kirby KC, Seymour BL. Contingency management for cocaine treatment: Cash
vs. vouchers. Journal of substance abuse treatment. 2014; 47(2): 168-74. doi: 10.1016/j.jsat.2014.03.001.
PMID: 24746956, PMCID: PMC4504189.
Preston KL, Ghitza UE, Schmittner JP, Schroeder JR, Epstein DH. Randomized trial comparing two
treatment strategies using prize-based reinforcement of abstinence in cocaine and opiate users. J Appl
Behav Anal. 2008; 41(4): 551-63. doi: 10.1901/jaba.2008.41-551. PMID: 19192859, PMCID:
PMC2606600.
Pirnia B, Tabatabaei SK, Tavallaii A, Soleimani AA, Pirnia K. The Efficacy of Contingency Management
on Cocaine Craving, using Prize-based Reinforcement of Abstinence in Cocaine Users. Electron Physician.
; 8(11): 3214-21. doi: 10.19082/3214. PMID: 28070254, PMCID: PMC5217813.
Kim JH, Lawrence AJ. Drugs currently in Phase II clinical trials for cocaine addiction. Expert Opin
Investig Drugs. 2014; 23(8): 1105-22. doi: 10.1517/13543784.2014.915312. PMID: 24773297.
Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, et al. Six-month trial of bupropion with
contingency management for cocaine dependence in a methadone-maintained population. Arch Gen
Psychiatry. 2006; 63(2): 219-28. doi: 10.1001/archpsyc.63.2.219. PMID: 16461866.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
